SynthesisFrontiers in pharmacology2023

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis.

Xueqiong Xun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.